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1  |  INTRODUC TION
Antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis 
(AAV) is characterised by necrotising vasculitis with few or no im-
mune complex deposits in the small vessels. AAV includes three sub-
types such as microscopic polyangiitis (MPA), granulomatosis with 
polyangiitis (GPA) and eosinophilic GPA (EGPA), based on clinical, 
laboratory, radiological and histological features.1,2 While the clini-
cal progression of AAV varies widely, if appropriate treatment is not 
provided or AAV is not responsive to treatment, AAV may recur or 
death may result from fatal complications.3,4 Therefore, active treat-
ment is required from the time of diagnosis of AAV, and indicators 
at diagnosis that can predict a poor prognosis during follow- up may 
be clinically useful.
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Abstract
Background: This study investigated whether the inflammation prognostic index (IPI) 
and the mortality predicting index (MPI) at diagnosis could predict all- cause mortal-
ity in patients with antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis 
(AAV).
Methods: We included 223 AAV patients and reviewed their medical records. Clinical 
and laboratory data and AAV- specific indices at diagnosis were assessed. The IPI was 
calculated as neutrophil- to- lymphocyte ratio (NLR) × C- reactive protein to albumin 
ratio (CAR). Here, we newly developed an MPI (NLR × CAR × monocyte counts).
Results: The mean age of 223 patients (122 MPA, 57 GPA and 44 EGPA patients) was 
59 years. The rate of mortality was 11.2%. Using the receiver operator characteristic 
curve for all- cause mortality, the cut- offs were calculated as NLR: 3.22, CAR: 3.25, IPI: 
18.53 and MPI: 8367.82. In the univariable Cox hazard analysis, age, gender, smoking 
history, BVAS, FFS and over the cut- off of each index showed statistical significance. 
As the indices share at least two mutual variables, the multivariable analysis was con-
ducted	four	times	based	on	each	index.	An	IPI	≥18.53	(HR	3.162)	and	MPI	≥8367.82	
(HR 3.356) were significantly associated with all- cause mortality.
Conclusions: This study developed a novel indicator, MPI, that uses the existing NLR 
and CAR indices and proved that it could predict all- cause mortality in AAV patients.
K E Y W O R D S
all- cause mortality, antineutrophil cytoplasmic antibody, inflammation prognostic index, 
Mortality- predicting index, vasculitis
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Various prognosis- predicting indices based on laboratory values 
at diagnosis have been suggested in tumour patients.5,6 The indi-
ces such as neutrophil- to- lymphocyte ratio (NLR) and C- reactive 
protein (CRP) to albumin ratio (CAR) have also shown clinical signif-
icance in AAV patients in that they could predict poor outcomes of 
AAV.7,8 These prognosis- predicting indices have merit as they use 
variables derived from the results of routinely performed laboratory 
tests at AAV diagnosis. Another advantage is that they are more sta-
ble and reliable through the mutual buffering effect between vari-
ables than a single variable such as ANCA type, gender, age, renal 
involvement and immunosuppressive agents at diagnosis.3,9
A new inflammation prognostic index (IPI) was recently intro-
duced and demonstrated to be useful for predicting the prognosis 
of non- small- cell lung cancer.10 The IPI is calculated as the product 
of two existing indices, NLR and CAR, which are useful for predict-
ing the prognosis of AAV.7,8 However, no studies have assessed its 
clinical significance in AAV patients. We recently proved that the 
systemic immune inflammatory index (SII), which includes platelet 
counts at diagnosis, and the pan- immune- inflammation value, which 
includes monocyte counts at diagnosis, could predict the poor out-
comes of AAV.11,12
Based on these concepts, we developed a novel index, the mortality- 
predicting index (MPI) which is calculated as NLR × CAR × monocyte 
counts at diagnosis. This study investigated whether the IPI and MPI 
at diagnosis could predict all- cause mortality during the follow- up. 
Furthermore, we compared the predictive potential for all- cause mor-
tality among the NLR, CAR, IPI and MPI in AAV patients.
2  |  PATIENTS AND METHODS
2.1  |  Study subjects
The medical records of 223 patients with AAV were retrospectively 
reviewed. All patients fulfilled both the 2007 European Medicines 
Agency algorithm and the 2012 revised International Chapel Hill 
consensus conference nomenclature of vasculitides.1,2 They had 
well- documented medical records to obtain clinical and laboratory 
results including the Birmingham Vasculitis Activity Score (BVAS), 
Five- Factor Score (FFS) and ANCA positivity at diagnosis.13,14 All pa-
tients were followed up for more than 3 months from AAV diagnosis. 
Patients with concomitant serious medical conditions such as ma-
lignancies, serious infections and end- stage organ damages at AAV 
diagnosis were excluded from this study. This study was approved by 
the Institutional Review Board (IRB) of Severance Hospital (4- 2020- 
1071), which waived the requirement for patient written informed 
consent due to the retrospective study design.
2.2  |  Clinical and laboratory data
At the time of AAV diagnosis, age, gender, smoking history and 
body mass index were collected as demographic data, and AAV 
subtype, ANCA positivity, BVAS and FFS were obtained as AAV- 
specific variables. Chronic kidney disease without renal replace-
ment therapy, diabetes mellitus, hypertension and dyslipidaemia 
were also evaluated as the initial comorbidities. During the follow-
 up, the number of patients who died from any cause was assessed. 
The follow- up duration based on all- cause mortality was defined 
as the period from AAV diagnosis to the last visit of the surviv-
ing patients and the date of death of the deceased patients. The 
medications administered during the follow- up duration were also 
investigated (Table 1).
2.3  |  Indices for predicting prognosis
(i) NLR = neutrophil counts (/μl) / lymphocyte counts (/μl)5 ; (ii) 
CAR = CRP (mg/L) / serum albumin (g/dl)6 ; (iii) IPI = NLR × CAR10 ; 
(iv) MPI = NLR × CAR × monocyte counts (/μl).
2.4  |  Statistical analyses
All statistical analyses were performed using IBM SPSS Statistics 
for Windows, version 25. (IBM Corp.). Continuous variables are ex-
pressed as medians with interquartile ranges and categorical vari-
ables as numbers (percentages). Significant differences between the 
two categorical variables were analysed using the chi- square and 
Fisher's exact tests. The optimal cut- off of each index for all- cause 
mortality was extrapolated by performing the receiver operator 
characteristic (ROC) curve analysis, and one value having the max-
imised sum of sensitivity and specificity was selected. Comparison 
of the cumulative survivals rates based on each cut- off between the 
two groups was analysed by the Kaplan- Meier survival analysis with 
the log- rank test. The multivariable Cox hazard model analysis using 
variables with statistical significance in the univariable analysis was 
conducted to appropriately obtain the hazard ratios (HRs) during the 
considerable follow- up durations.
3  |  RESULTS
3.1  |  Characteristics at diagnosis
The mean age of the study subjects (33.2% men) was 59.0 years. 
Six patients had been exposed to smoking, and the mean body 
mass index was 22.2 kg/m2. This study included 122 MPA patients, 
57 GPA patients and 44 EGPA patients. Myeloperoxidase (MPO)- 
ANCA (or perinuclear (P)- ANCA) and proteinase 3 (PR3)- ANCA (or 
cytoplasmic (C)- ANCA) were detected in 148 and 38 patients, re-
spectively, whereas no ANCA was found in 46 patients. The me-
dian BVAS and FFS were 2.0 and 1.0, respectively, and the most 
common comorbidity was hypertension (40.4%). The mean NLR, 
CAR, IPI and MPI values were 4.4, 3.2, 15.6 and 4893.2, respec-
tively (Table 1).
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3.2  |  Characteristics during follow- up
Twenty- five patients (11.2%) died of any cause during 36.5 months 
of the median follow- up duration based on all- cause mortality. 
Glucocorticoids were administered to 207 patients (92.8%). The 
most frequently administered medication, except for glucocorticoid, 
was azathioprine (53.8%), followed by cyclophosphamide (50.2%) 
(Table 1). No significant differences in medications administered were 
observed between the surviving and deceased patients (Table S1).
3.3  |  Areas under the curve and cut- offs for all- 
cause mortality
Regarding the ROC curves of the four indices for all- cause mortality, 
the MPI exhibited the highest area under the curve (AUC) (0.691, 
95% confidence interval [CI] 0589, 0.792), followed by the IPI (0.686, 
95% CI 0.587, 0.786) (Figure 1). The optimal cut- offs for all- cause 
mortality were calculated as NLR: 3.22 (sensitivity 92.0%, specificity 
40.4%), CAR: 3.25 (sensitivity 80.0%, specificity 55.1%), IPI: 18.53 
(sensitivity 80.0%, specificity 57.6%) and MPI: 8367.82 (sensitivity 
76.0%, specificity 59.1%).
3.4  |  Comparison of the cumulative survival rates
The cumulative patients' survival rates were significantly lower in pa-
tients	with	an	NLR	≥3.22	(p	=	0.001),	CAR	≥3.25	(p	=	0.004),	IPI	≥18.53	
(p	<	0.001)	and	MPI	≥8367.82	(p = 0.001) than those without (Figure 2).
3.5  |  Hazard ratios of the indices for all- cause 
mortality during follow- up
In the univariable Cox hazards model analysis, age, gender, smok-
ing	history,	BVAS,	FFS,	NLR	≥3.22,	CAR	≥3.25,	IPI	≥18.53	and	MPI	
≥8367.82	 showed	 statistical	 significance	 (Table	 S2).	 As	 the	 four	
Variables Values
Calcineurin inhibitor 12 (5.4)
Methotrexate 22 (9.9)
Plasma exchange 13 (5.8)
Note: Values are expressed as a median (interquartile range, IQR) or N (%).
Abbreviations: AAV, ANCA- associated vasculitis; ANCA, antineutrophil 
cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; C, 
cytoplasmic; CAR, C- reactive protein- to- albumin ratio; EGPA, eosinophilic 
GPA; FFS, Five- Factor Score; GPA, granulomatosis with polyangiitis; 
IPI, inflammation prognostic index; MPA, microscopic polyangiitis; MPI, 
mortality- predicting index; MPO, myeloperoxidase; NLR, neutrophil- to- 
lymphocyte count ratio; P, perinuclear; PR3, proteinase 3.
aPatients who took renal replacement therapy (negative follow- up 
duration) were not included in this study because end- stage renal 
disease is one of poor outcomes.





Age (years) 59.0 (20.0)
Male gender (N, (%)) 74 (33.2)
Smoking history (N, (%)) 6 (2.7)
Body mass index (kg/m2) 22.2 (4.4)




ANCA positivity (N, (%))
MPO- ANCA (or P- ANCA) positivity 148 (66.4)
PR3- ANCA (or C- ANCA) positivity 38 (17.0)
Both ANCA positivity 9 (4.0)




Comorbidities at diagnosis (N, (%))
Chronic kidney disease without renal 
replacement therapya 
66 (29.6)
Serum creatinine (mg/dl) 0.9 (1.1)
Diabetes mellitus 53 (23.8)
Hypertension 90 (40.4)
Dyslipidaemia 37 (16.6)






Follow- up duration (months) 36.2 (63.3)
Poor outcomes
All- cause mortality (N, (%)) 25 (11.2)








Mycophenolate mofetil 28 (12.6)
(Continues)
Table	1 (Continued)
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indices share at least two mutual variables, the multivariable analy-
sis included age, gender, smoking history, BVAS, FFS and each of 
the four prognosis- predicting indices. In the multivariable analysis 
with	 the	NLR,	only	an	NLR	≥3.22	at	diagnosis	 (HR	5.367,	95%	CI	
1.188, 24.252) was an independent predictor of all- cause mortality. 
In the multivariable analysis with the CAR, the CAR was not discov-
ered as an independent predictor of all- cause mortality. Instead, 
gender and FFS at diagnosis was significantly associated with 
all- cause mortality. In the multivariable analysis with the IPI, only 
an	IPI	≥18.53	at	diagnosis	(HR	3.162,	95%	CI	1.128,	2.513)	was	an	
independent predictor of all- cause mortality. In the multivariable 
analysis	with	 an	MPI	≥8367.82	 (HR	3.356,	95%	CI	1.290,	 8.735),	
smoking history and FFS at diagnosis were significantly associated 
with all- cause mortality (Table 2). We confirmed no significant mul-
ticollinearity among continuous variables in the multivariable Cox 
hazard model analysis.
F I G U R E  1 Area	under	the	curve	
of each index for all- cause mortality. 
Regarding the ROC curves of the four 
indices for all- cause mortality, the MPI 
exhibited the highest AUC value, followed 
by the IPI. AUC, area under the curve; 
IPI, inflammation prognostic index; MPI, 
mortality- predicting index; ROC, receiver 
operator characteristic
F I G U R E  2 Cumulative	patient	survival	rates.	The	cumulative	patient	survival	rates	were	significantly	lower	in	patients	with	an	NLR	≥3.22,	
CAR	≥3.25,	IPI	≥18.53	and	MPI	≥8367.82	than	those	without.	CAR,	C-	reactive	protein-	to-	albumin	ratio;	IPI,	inflammation	prognostic	index;	
MPI, mortality- predicting index; NLR, neutrophil- to- lymphocyte count ratio
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4  |  DISCUSSION
The motive for performing this study was the question of whether 
the IPI, which has been reported to predict survival- related prog-
nosis in tumour patients, could predict all- cause mortality in AAV 
patients.10 As the IPI is calculated as the product of the NLR and 
CAR, which have been reported to predict poor outcomes in AAV 
patients, positive conclusions were expected from the start of the 
study. In addition, we modified the IPI (NLR × CAR) to develop a new 
index, MPI, using monocyte counts, which were closely associated 
with all- cause mortality in previous studies.7,8
In the ROC curve analysis performed to obtain the cut- offs for 
all- cause mortality, all four indices showed statistically significant 
AUC values, although the follow- up duration based on mortality 
was not considered. Interestingly, the IPI, which is the product of the 
NLR and CAR, showed a higher AUC value than that of either NLR or 
CAR alone. In particular, the MPI, which includes monocyte counts 
combined with IPI, showed the highest AUC value. The addition of 
monocyte counts completed the three lineages of white blood cells 
and increased the predictability of the mortality rate. There are sev-
eral possible mechanisms of how monocytes could predict all- cause 
mortality through the relationship between the early inflammatory 
burden and mortality in AAV patients.15 ANCAs stimulate the pro-
duction of monocyte chemoattractant portien- 1, pro- inflammatory 
cytokines and reactive oxygen species (ROS), which subsequently 
drive monocytes to persist local inflammation around small vessel 
walls.16- 18
The mortality predictabilities of the four indices based on the 
follow- up duration were compared in two univariable variable analy-
ses. In the Kaplan- Meier analysis, the predictive power for all- cause 
mortality	was	best	for	an	IPI	≥18.53	(p < 0.001) for all- cause mortal-
ity	was	found	to	be	the	best,	followed	by	an	NLR	≥3.22	(p = 0.001) 
and	MPI	≥8367.82	 (p = 0.001). In addition, in the univariable Cox 
hazard	model	analysis,	the	predictive	potential	of	an	IPI	≥18.53	(HR	
4.976, p	=	0.001)	was	the	highest,	followed	by	an	MPI	≥8367.82	(HR	
4.378, p = 0.002). In both univariable analyses, the mortality predict-
ability of the IPI was statistically the most significant.
Meanwhile, to be recognised for clinical significance as an inde-
pendent predictor for all- cause mortality, the multivariable analysis 
must show superior or similar mortality predictive ability compared 
with the conventional risk factors. In this respect, in the multivari-
able	 analysis,	 although	 all	 four	 indices	 except	 CAR	 ≥3.25	 showed	
TA B L E  2 Multivariable	Cox	hazards	model	analysis	of	variables	at	diagnosis	statistical	significance	in	univariable	analysis	for	all-	cause	
mortality during follow- up in AAV patients
Variables at 
diagnosis
Univariable Multivariable (NLR ≥3.22) Multivariable (CAR ≥3.25)
HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value
Age (years) 1.055 1.018, 1.093 0.003 1.031 0.995, 1.067 0.093 1.029 0.994, 1.066 0.108
Male gender (N, (%)) 2.264 1.029, 4.978 0.042 0.575 0.242, 1.366 0.210 0.406 0.179, 0.919 0.031
Smoking history (N, 
(%))
6.052 1.787, 20.498 0.004 0.285 0.070, 1.158 0.079 2.774 0.739, 10.417 0.131
BVAS 1.096 1.040, 1.155 0.001 1.052 0.992, 1.115 0.090 1.037 0.978, 1.101 0.226
FFS 2.142 1.468, 3.126 <0.001 1.483 0.945, 2.326 0.086 1.716 1.086, 2.713 0.021
NLR	≥3.22 7.525 1.773, 31.945 0.006 5.367 1.188, 24.252 0.029
CAR	≥3.25 3.872 1.451, 10.336 0.007 2.317 0.836, 6.421 0.106
IPI	≥18.53 4.967 1.860, 13.263 0.001
MPI	≥8367.82 4.378 1.746, 10.979 0.002
Variables at diagnosis
Multivariable (IPI ≥18.53) Multivariable (MPI ≥8367.82)
HR 95% CI p Value HR 95% CI p Value
Age (years) 1.028 0.993, 1.064 0.114 1.024 0.989, 1.061 0.183
Male gender (N, (%)) 2.181 0.947, 5.022 0.067 1.995 0.859, 4.633 0.108
Smoking history (N, (%)) 3.910 0.984, 15.529 0.053 4.116 1.021, 16.596 0.047
BVAS 1.039 0.980, 1.102 0.196 1.041 0.983, 1.102 0.170
FFS 1.575 0.988, 2.513 0.056 1.861 1.134, 3.054 0.014
NLR	≥3.22
CAR	≥3.25
IPI	≥18.53 3.162 1.128, 8.861 0.029
MPI	≥8367.82 3.356 1.290, 8.735 0.013
Abbreviations: AAV, ANCA- associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CAR, 
CRP- to- albumin ratio; CI, confidence interval; CRP, C- reactive protein; FFS, Five- Factor Score; HR, hazard ratio; IPI, inflammation prognostic index; 
MPI, mortality- predicting index; NLR, neutrophil- to- lymphocyte ratio.
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significant	significance,	MPI	≥8367.82	showed	the	most	statistically	
significant association (p = 0.013), making it the most valid measure 
for clinical application.
The conventional risk factors for all- cause mortality not only in 
the general population19 but also in AAV patients may differ accord-
ing to ethnic and geographical factors. In addition, the clinical impli-
cations of the laboratory results constituting the four indices may be 
influenced by environmental factors. Therefore, two points should 
be kept in mind when selecting and applying the most significant 
mortality- predicting index for AAV patients based on the results of 
the multivariable analysis of this study. First, an index should be se-
lected, in which the mortality predictability is independently equal 
to or superior to the conventional risk factors for all- cause mortality 
with statistical significance in the multivariable Cox hazards model 
analysis.19 Second, the cut- off of each index for all- cause mortality 
suggested in this study should not be used directly, and new cut- 
offs suitable for each ethnic group or region should be determined 
according to the described method.
For these reasons, we added several variables with clinical sig-
nificance to the multivariable Cox analysis such as AAV- specific risk 
factors and comorbidities at diagnosis, despite no statistical signifi-
cance in the univariable Cox analysis. In the multivariable Cox anal-
ysis, MPO- ANCA, PR3- ANCA, chronic kidney disease without renal 
replacement therapy, diabetes mellitus, hypertension and dyslipi-
daemia did not independently predict all- cause mortality. However, 
an	MPI	≥8367.82	(HR	4.698,	95%	CI	1.657,	13.315)	was	proved	to	be	
an independent predictor of all- cause mortality during the follow- up 
in AAV patients along with the FFS (HR 2.219, 95% CI 1.187, 3.818) 
(Table S3).
What is the clinical significance of the efforts to develop new 
mortality- predicting indices? The overall mortality rate in this study 
was 11.2%, which is a much higher value than other rheumatic 
diseases.20- 22 It was not possible to accurately assess how drug 
selection and the follow- up duration were determined due to the 
retrospective study design. However, if AAV patients were classified 
into a group with a high probability of mortality, more care would 
likely have been put into these decisions. Therefore, the continued 
development of various mortality- predicting indices is needed.
This study has three strengths. First, we conducted a multivari-
able Cox hazards model analysis using the candidate indices with 
the conventional risk factors for mortality. Second, we developed 
and proposed new indices with higher predictability than previously 
reported mortality- predicting indices. Third, to overcome the ethnic 
and geographical differences, we suggested a method of determining 
a cut- off for predicting mortality for each index. However, this study 
also has three limitations. First, due to the retrospective nature of this 
study, the cause of death was not definitely provided in all patients 
with AAV. Second, the number of patients was not large enough to 
represent all Korean patients with AAV. Third, our results were not 
validated by another cohort of Korean patients with AAV because, 
in terms of the number of patients and the collection of clinical data 
and specimen data, there is no cohort of Korean patients with AAV 
as large, specific and robust as our cohort. Nationwide data on the 
prognosis of Korean patients with AAV are being collected and will 
provide more informative evidence regarding the clinical significance 
of each index for predicting all- cause mortality during the follow- up.
In conclusion, this study developed a novel indicator, MPI, that 
uses the existing NLR and CAR indices and proved they could pre-
dict all- cause mortality in AAV patients. New prognosis- predicting 
indices at diagnosis are expected to improve the prognosis of AAV.
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